Insight to Execution: How AI Must Evolve to Transform Clinical Development
The early stages of drug development have benefited greatly from artificial intelligence. Target identification, molecule design, and lead optimization have all gotten faster. Yet clinical development, where most of the time and cost actually sit, remains slow. The work is scattered across sponsors, CROs, sites, and regulators. The AI capability is there, but the problem is the lack of integrated systems that connect the people and data that drive clinical decisions at scale. Three challenges explain why:
Challenge 1: Patient recruitment and retention remain unsolved
Despite years of investment in AI tools, the same problem keeps stalling trials: patients are not enrolling fast enough, and those who do are not staying.
- Nearly 80% of clinical trials are delayed due to recruitment problems1
- Up to 85% of trials fail to recruit enough participants to meet predefined targets1
- More than one-third of research sites fail to meet original enrollment goals, and 11% of sites fail to enroll a single patient2
- Even when patients are enrolled, drop-out rates average around 30%, which ruins data integrity and inflates costs and timelines3
These problems have persisted because most AI tools in clinical development are designed to predict rather than act. They largely focus on identifying high-probability candidates, scoring eligibility, or forecasting enrollment trends. The models aren’t the issue; getting patients into trials and keeping them there is actually a workflow problem.
Patients don't enroll because they may never hear about a trial, or because sites lack the capacity to follow up effectively, or because logistics create barriers before consent is ever signed. Patients drop out because visit schedules are burdensome, communication is inadequate, or the perceived value of participation fades over time.
What must change: AI has to evolve from a classification tool into a coordination engine. It has to trigger outreach when a candidate surfaces, coordinate follow-up across CROs and sites, and reduce the burden that keeps patients from showing up or staying enrolled.
Building that system requires a partner with deep clinical operations experience and the platform infrastructure to connect predictive models to instant action. The technology to identify candidates already exists, but what’s missing is the operational layer that acts on those signals immediately, across every stakeholder involved in the trial.
Challenge 2: Clinical research is still trapped in a document mindset
There’s a more foundational problem underneath the recruitment challenge. Study designs, specifications, and regulatory intent still live in static documents. Protocols, Statistical Analysis Plans, and define.xml descriptions have to be interpreted, re-keyed, and translated into system-specific implementations at every handoff. Each translation adds delay, cost, and risk. Automation, where it exists, is layered on top of manual interpretation rather than designed in from the start.
The fix is structural: study design has to become a machine-readable framework from the start, so that the path from protocol definition through analysis and regulatory submission can be automated.
- Digitizing study design at the source to make protocols machine-readable from inception, enabling automated EDC configuration, reduced system rework, and executable study definitions
- Shifting from code-driven to metadata-driven transformation logic so that changes are made once and propagated automatically, with full auditability and end-to-end data lineage
- Embedding traceability into regulatory submissions, allowing reviewers to navigate from analysis results back through transformation logic to source data, reducing review cycles and improving transparency
This is what moves AI’s role beyond point solutions. When data and logic are standardized, AI can reason, automate impact analysis, and propagate changes consistently at scale. It can support decisions that today require manual interpretation. Without that foundation, every AI tool is a standalone experiment.
Going from a document-driven study design to a data-driven one demands a partner that understands both the regulatory framework and the technical architecture required to make protocols machine-readable from day one. Few organizations have the combined regulatory science and data engineering depth to deliver this at scale.
Challenge 3: Disconnected pilots are not a strategy
The third challenge is strategic: the industry's current approach to AI adoption is holding back its own potential. Most organizations have accumulated pilot tools and point solutions that work in isolation. The tools produce local efficiencies, but enrollment velocity, trial timelines, and submission quality haven’t improved in proportion to the investment.
What replaces this pilot mindset is an orchestrated platform approach in which AI tools share data standards, operate across workflow stages, and escalate to humans when judgment is required. Five characteristics define what that looks like in practice:
- Protocol design as a system problem: Integrated AI platforms can simulate protocol scenarios before designs are locked, combining scientific data, operational constraints, and competitive intelligence to produce better-balanced studies without compromising rigor.
- Clinical development as a unified operating system: Leading organizations are moving toward coordinated AI ecosystems where intelligent agents operate on shared data standards, execute end-to-end workflows, and escalate to humans only when judgment or regulatory interpretation is required.
- Real-time data reasoning instead of retrospective analysis: When clinical data is interoperable across CTMS, EHR, ePRO, and vendor systems, AI can support earlier detection of enrollment risks and proactive course correction while studies are still in motion.
- AI-Augmented execution models: Frameworks such as RAPID (Recommend, Agree, Perform, Input, Decide) become operationalized: agentic systems handle routine coordination and quality checks, while humans focus on oversight and high-stakes decisions. The result is a thinner execution layer, faster decisions, and less organizational drag.
- Material business impact: Integrated AI platforms are projected to accelerate clinical development timelines by 20–30%. For large sponsors, this translates to earlier regulatory submissions and faster patient access, translating to hundreds of millions of dollars in earlier revenue per asset.
Moving from pilot-stage tools to an orchestrated platform requires a partner that can operate across the full development lifecycle, from protocol design through submission, with shared data standards and the ability to coordinate AI agents across workflow stages.
The unifying principle: Orchestration over analytics
The argument across all three challenges is the same. AI will not transform clinical development through more sophisticated models working in silos. It will do so when it is built as an orchestrated, single intelligent system. Prediction connects to operational execution, study design becomes machine-readable from the start, and pilot tools give way to platforms that share data and workflows across the development lifecycle.
The patient at the center
Recruitment delays and fragmented data, compounded by disconnected tools, lead to longer timelines and delayed access for patients waiting for therapies that science has already made possible.
Integrated platforms can begin to close the gap between AI’s predictive power and clinical operations’ ability to act on it. There are enough AI pilots in clinical development. Now it needs the right foundation oriented around the patient from the start.
The right partner for clinical development success
Axtria is building toward this vision of orchestrated clinical intelligence. Our platform connects the full trial lifecycle: protocol design and digital twin simulation, patient identification from structured and unstructured data, site feasibility and enrollment forecasting, real-time operational surveillance, AI-assisted CSR generation, and CDISC-compliant data transformation.
Several core capabilities are already in production. LUCCID extracts data from unstructured clinical documents. Rapid CSR accelerates clinical report authoring. Our EXPERT agent architecture supports feasibility and enrollment intelligence. These tools are delivering concrete results: greater than 90% accuracy in rare disease patient identification and 85% enrollment forecast accuracy. Other elements, including multi-level digital twin simulation, adaptive operational orchestration, and end-to-end agentic workflows, are in active development, shaped by real client engagements and grounded in a data foundation of 300+ managed sources.
Alongside this platform, Axtria brings clinical execution capability today: hands-on data management from acquisition through database lock and independent technology consulting for platform selection and GxP implementation. Axtria also brings a human-centric trial design that quantifies patient burden and builds the experience around the participant.
With 450+ data scientists and 500+ data engineers, supported by 50+ clinical domain experts operating across 70+ geographies, Axtria combines the delivery infrastructure to execute now with a clear roadmap toward connected, scalable clinical operations.
References:
- Parexel (Sponsored). Decentralized clinical trials: are we ready to make the leap? 2019 Jan 29 [cited 2026 Apr 3]. In: Biopharma Dive [Internet]. Newton, MA: Informa TechTarget. Available from: https://www.biopharmadive.com/spons/decentralized-clinical-trials-are-we-ready-to-make-the-leap/546591/
- Peters S. New research from Tufts Center for the Study of Drug Development characterizes effectiveness and variability of patient recruitment and retention practices. 2013 Jan 15 [cited 2026 Apr 3]. In: Fierce Biotech [Internet]. Tufts Center for the Study of Drug Development. Available from: https://www.fiercebiotech.com/biotech/new-research-from-tufts-center-for-study-of-drug-development-characterizes-effectiveness
- National Research Council (US) Panel on Handling Missing Data in Clinical Trials. The prevention and treatment of missing data in clinical trials. Washington (DC): National Academies Press (US); 2010. PMID: 24983040.
FAQs
Most AI tools in recruitment focus on identifying candidates or predicting enrollment. Those models work, but enrollment still stalls because there’s no follow-through. Patients never hear about the trial, sites can't follow up fast enough, or logistics create friction. The only way to solve this is by evolving AI from a classification tool into a coordination engine. That way, it triggers outreach in real time, manages follow-up across sponsors/CROs/sites, and reduces the day-to-day burden that causes patients to drop out.
Today, study designs live in static documents like protocols or analysis plans. They’re manually interpreted and often re-entered, bringing delay and risk each time. Making protocols machine-readable means structuring study logic as data from inception, so downstream systems can read it. Traceability is built in. This is what allows AI to reason across the study lifecycle rather than operate as a set of disconnected point solutions.
When AI connects every part of the clinical process in a single, orchestrated platform, organizations can reduce rework, delays, and manual interpretation that slow every phase. Faster enrollment means shorter trial timelines. Machine-readable study designs mean fewer handoff errors. For large sponsors, even modest acceleration translates to earlier revenue per asset and faster patient access to therapies. The ROI scales with integration.
Most organizations have adopted AI through a series of pilots and single-point solutions that each solve a narrow problem well. But improvement isn’t proportional because those tools don't share data. The missing piece is orchestration: a platform approach where AI agents work from shared data standards, execute across the full study lifecycle, and escalate to humans when regulatory interpretation or strategic judgment is required.
This means connecting AI capabilities so that predictive outputs trigger operational actions. In practice, that looks like protocol simulation before study designs are locked, automated patient identification from structured and unstructured data, real-time enrollment surveillance that flags risks while a trial is still in motion, and AI-assisted report generation that maintains full data lineage through submission. Execution frameworks like Axtria’s LUCCID or Rapid CSR define where agentic systems handle routine coordination and where humans retain oversight. The result is faster decisions and fewer manual bottlenecks at each stage.